U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
News Apr 04, 2008
U.S. Preventive Medicine® and deCODE Genetics announced they have signed a letter of intent to add genetic testing to expand both companies' personalized medicine services in the U.S. and internationally.
"The signing of the letter of intent with deCODE is significant because we will be the first entity in the U.S. and internationally to offer a full continuum of geographically dispersed, comprehensive solutions for personalized medicine including preventive care, wellness and disease management," said Christopher Fey, Chairman and CEO of U.S. Preventive Medicine.
"We are very excited because our consumer, employer and physician customers will now be able to take advantage of a wide range of innovative personalized medicine services, including an opt-in genetic testing program for clients of our Centers for Preventive Medicine and members of The Prevention Plan. Our goal is to make the most advanced prevention strategies -- including more precise risk stratification -- available to informed consumers who want to use the best medicine has to offer to enjoy more good years."
Fey said U.S. Preventive Medicine's expansion into personalized medicine is the next step in the company's plan to provide practical solutions at every point in the healthcare continuum both nationally and internationally.
"The relationship with U.S. Preventive Medicine will offer us another platform to provide our genetic testing and personal genetics services through an innovative business model encompassing Centers for Preventive Medicine, as well as its new Prevention Plan health benefits," says Kari Stefansson, M.D., CEO of deCODE.
"This partnership gives deCODE access to an even wider distribution channel of consumers, employers and providers to share knowledge, experiences, new technologies and services, while providing the best possible preventive health programs."
According to U.S. Preventive Medicine National Policy Advisor and former Secretary of the U.S. Department of Health & Human Services, Gov. Tommy Thompson, "The addition of deCODE's DNA profiling services as a option for the individuals the company assists is a natural evolution in the direction of the demand for personalized medicine. This is a very important step for U.S. Preventive Medicine in their role as the leader of this crucial area of health care."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.